Increased Serum Sclerostin Levels in Patients With Active Acromegaly

Basit Öğe Kaydı
dc.contributor.authorPekkolay, Zafer
dc.contributor.authorKilinc, Faruk
dc.contributor.authorGozel, Nevzat
dc.contributor.authorOnalan, Ebru
dc.contributor.authorTuzcu, Alpaslan Kemal
dc.date.accessioned2024-04-24T17:15:01Z
dc.date.available2024-04-24T17:15:01Z
dc.date.issued2020
dc.departmentDicle Üniversitesien_US
dc.description.abstractContext: Bone mineral density is normal in acromegalic patients and the cause of increased fracture risk that characterizes active acromegaly is unknown. Objective: This study compared serum sclerostin levels between patients with active acromegaly and healthy individuals. Design, Setting, and Participants: The serum sclerostin levels of patients with active acromegaly were compared with those of healthy volunteers in a cross-sectional study. The mean age of the 30 acromegaly patients (male/female: 14/16) was 47.26 +/- 12.52 years (range, 18-64 years) and that of the healthy volunteers (male/female: 17/13) was 44.56 +/- 10.74 years (range, 19-62 years). IGF-1 and GH levels were measured using an electrochemiluminescence method, and serum sclerostin levels using an ELISA. The Mann-Whitney U test was used to compare sclerostin levels between the 2 groups. The correlations of sclerostin level with IGF-1 and GH were determined using Spearman's test. Results: The 2 groups did not differ in age or sex (P > 0.05). The median GH and IGF-1 levels in the patient group were 2.49 ng/mL (range, 0.22-70.00 ng/mL) (interquartile range [IQR], 1.3-4.52) and 338.5 ng/mL (range, 147-911 ng/mL) (IQR, 250-426), respectively. The median GH and IGF-1 levels in the control group were 0.95 ng/mL (range, 0.3-2.3) and 144 ng/mL (range, 98-198), respectively. The median sclerostin level was 29.95 ng/mL (range, 7.5-78.1 ng/mL) (IQR, 14.37-37.47) in the acromegaly group and 22.44 ng/mL (range, 8.45-36.44 ng/mL) (IQR, 13.71-27.52) in the control group (P < 0.05). There was a moderate positive correlation between the sclerostin and IGF-1 levels (rho = 0.54; P < 0.01), and between the sclerostin and GH levels (rho = 0.41; P < 0.05). Conclusions: High sclerostin levels may contribute to the increased fracture risk seen in patients with acromegaly.en_US
dc.identifier.doi10.1210/clinem/dgz254
dc.identifier.endpage924en_US
dc.identifier.issn0021-972X
dc.identifier.issn1945-7197
dc.identifier.issue3en_US
dc.identifier.pmid31821453
dc.identifier.scopus2-s2.0-85081167217
dc.identifier.scopusqualityQ1
dc.identifier.startpage920en_US
dc.identifier.urihttps://doi.org/10.1210/clinem/dgz254
dc.identifier.urihttps://hdl.handle.net/11468/18304
dc.identifier.volume105en_US
dc.identifier.wosWOS:000525870500136
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherEndocrine Socen_US
dc.relation.ispartofJournal of Clinical Endocrinology & Metabolism
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSclerostinen_US
dc.subjectAcromegalyen_US
dc.subjectOsteoporosisen_US
dc.titleIncreased Serum Sclerostin Levels in Patients With Active Acromegalyen_US
dc.titleIncreased Serum Sclerostin Levels in Patients With Active Acromegaly
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu